UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): June 24, 2020 

 


 

OXFORD IMMUNOTEC GLOBAL PLC

(Exact name of registrant as specified in its charter) 

 


 

England and Wales

(State or other jurisdiction of incorporation)

 

001-36200

98-1133710

(Commission File Number)

(IRS Employer Identification No.)

 

94C Innovation Drive, Milton Park, Abingdon OX14 4RZ, United Kingdom

(Address of principal executive offices)

 

Registrant’s telephone number including area code: +44 (0) 1235 442780 

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol

Name of each exchange on which

registered

Ordinary Shares, £0.006705

nominal value per share

OXFD

The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On June 24, 2020, Oxford Immunotec Global PLC (the “Company”) held its 2020 annual general meeting of shareholders (the “Meeting”). The resolutions set forth below were voted on and duly passed at the Meeting. Detailed descriptions of these resolutions and of the voting procedures applied at the Meeting are contained in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2020.

 

The final voting results for the Meeting are as follows:

 

Proposal

Number

Proposal

Description

For

Against

Abstain

Broker

Non-votes

1

Election of Patrick J. Balthrop, Sr.

18,427,592

2,384,476

0

1,656,273

2

Election of Patricia Randall

18,592,123

2,219,945

0

1,656,273

3

Election of Herm Rosenman

20,553,336

258,732

0

1,656,273

4

Ratification of Appointment of Ernst & Young LLP, the U.S. member firm of Ernst & Young Global Limited as the Company’s Auditors for 2020

22,452,848

15,493

0

0

5

Re-Appointment of the U.K. member firm of Ernst & Young Global Limited, Ernst & Young LLP as the Company’s U.K. Statutory Auditors

22,452,848

15,493

0

0

6

Authorization to Determine Statutory Auditors’ Remuneration for 2020

22,466,621

1,498

222

0

7

Receive U.K. Statutory Accounts and Reports for 2020

22,352,240

0

116,101

0

8

Receive and Approve U.K. Statutory Directors’ Annual Report on Remuneration for 2019

20,619,173

191,395

1,500

1,656,273

9

Non-Binding Approval of Compensation Paid to our Named Executive Officers

20,616,295

193,223

2,550

1,656,273

10

Approval of Directors’ Remuneration Policy

18,317,841

2,491,528

2,699

1,656,273

11

Authorization of our Board of Directors to Allot Ordinary Shares

17,766,792

4,697,241

4,308

0

12

Approval of General Disapplication of Pre-Emption Rights with respect to Allotment of Ordinary Shares

17,958,737

4,505,072

4,532

0

13

Authorization of our Board of Directors to Issue up to Maximum Amount of New Shares

17,957,470

4,506,339

4,532

0

 

Resolutions 1 through 11 were ordinary resolutions, and each resolution was passed as the number of votes cast in favor exceeded the number of votes cast against each such proposal. Resolutions 12 and 13 were special resolutions, and each was passed as at least 75% in nominal value of the outstanding shares entitled to vote at the Meeting were cast in favor for each of the special resolutions.

 

 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 25, 2020

 

 

OXFORD IMMUNOTEC GLOBAL PLC

 

 

 

 

By:

/s/ Matthew T E McLaughlin

 

 

Matthew T E McLaughlin

 

 

Chief Financial Officer